160 related articles for article (PubMed ID: 2434595)
1. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.
Wohlwend A; Belin D; Vassalli JD
J Exp Med; 1987 Feb; 165(2):320-39. PubMed ID: 2434595
[TBL] [Abstract][Full Text] [Related]
2. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
3. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Genton C; Kruithof EK; Schleuning WD
J Cell Biol; 1987 Mar; 104(3):705-12. PubMed ID: 3102504
[TBL] [Abstract][Full Text] [Related]
4. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator-specific inhibitors in mouse macrophages: in vivo and in vitro modulation of their synthesis and secretion.
Wohlwend A; Belin D; Vassalli JD
J Immunol; 1987 Aug; 139(4):1278-84. PubMed ID: 3112228
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid potentiates phorbol ester-mediated induction of urokinase and plasminogen activator inhibitor type 2 in human myeloid leukemic cell lines.
Schuster WA; Medcalf RL; Kruithof EK
Endocrinology; 1993 Oct; 133(4):1724-30. PubMed ID: 8404615
[TBL] [Abstract][Full Text] [Related]
7. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.
Picone R; Kajtaniak EL; Nielsen LS; Behrendt N; Mastronicola MR; Cubellis MV; Stoppelli MP; Pedersen S; Danø K; Blasi F
J Cell Biol; 1989 Feb; 108(2):693-702. PubMed ID: 2537321
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mouse L-cells with phorbol myristate acetate induces the secretion of a plasminogen activator inhibitor which binds to human and mouse urokinase and human tissue plasminogen activator.
Rehemtulla A; Gates J; Hart DA
Comp Biochem Physiol B; 1987; 88(1):277-83. PubMed ID: 3119281
[TBL] [Abstract][Full Text] [Related]
10. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.
Vassalli JD; Dayer JM; Wohlwend A; Belin D
J Exp Med; 1984 Jun; 159(6):1653-68. PubMed ID: 6374011
[TBL] [Abstract][Full Text] [Related]
11. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
Schleef RR; Wagner NV; Loskutoff DJ
J Cell Physiol; 1988 Feb; 134(2):269-74. PubMed ID: 3257967
[TBL] [Abstract][Full Text] [Related]
12. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator.
Karhumäki E; Saravo L; Helin H
J Leukoc Biol; 1987 Jul; 42(1):36-42. PubMed ID: 3298513
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.
Kruithof EK; Vassalli JD; Schleuning WD; Mattaliano RJ; Bachmann F
J Biol Chem; 1986 Aug; 261(24):11207-13. PubMed ID: 3090045
[TBL] [Abstract][Full Text] [Related]
14. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
15. Alveolar macrophage urokinase receptors localize enzyme activity to the cell surface.
Chapman HA; Bertozzi P; Sailor LZ; Nusrat AR
Am J Physiol; 1990 Dec; 259(6 Pt 1):L432-8. PubMed ID: 2175557
[TBL] [Abstract][Full Text] [Related]
16. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
Estreicher A; Mühlhauser J; Carpentier JL; Orci L; Vassalli JD
J Cell Biol; 1990 Aug; 111(2):783-92. PubMed ID: 2166055
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
18. Differences between the F10, BL6 and F1 sublines of the B16 melanoma in the enhancement of plasminogen activator and plasminogen activator inhibitor secretion by phorbol myristate acetate.
Hart DA; Smith R
Cancer Lett; 1987 Apr; 35(1):27-38. PubMed ID: 3105864
[TBL] [Abstract][Full Text] [Related]
19. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
Wun TC; Reich E
J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Niiya K; Nsimba M; Hayashi T; Sakuragawa N
Thromb Res; 1992 Feb; 65(3):311-21. PubMed ID: 1631798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
